CMT Targets Cancer, Prenatal Testing Markets In China
This article was originally published in The Gray Sheet
Executive Summary
China Medical Technologies plans to exploit China's efforts to expand health care access by launching prenatal and postnatal tests as well as cancer diagnostics based on newly acquired fluorescent in situ hybridization technology